Citius Pharmaceuticals, Inc. quarterly report, Q1 FY2023

Full document

Citius Pharmaceuticals, Inc. — Form 10-Q Summary

Reporting period: Fiscal first quarter ended December 31, 2022; unaudited consolidated results compared with the three months ended December 31, 2021. Citius is a development-stage pharmaceutical company focused on oncology, anti-infectives, prescription products and stem-cell therapies. It reported no operating revenue in either period.

Financial performance and liquidity

  • Revenue: $0 in both periods; margins are not meaningful without revenue.
  • Operating expenses and loss: Operating expenses were $7.25 million, down from $9.26 million. The operating loss was $7.25 million, versus $9.26 million.
  • Research and development: $3.45 million, down $2.01 million year over year. I/ONTAK spending fell after its BLA filing; Mino-Lok spending increased as the Phase 3 trial expanded to additional sites.
  • General and administrative: $2.60 million, down from $2.90 million. Stock-based compensation, reported separately, rose to $1.20 million from $0.90 million.
  • Net loss: $3.59 million, or $0.02 per share, versus $9.23 million, or $0.06 per share. The improvement included a $3.59 million gain from selling New Jersey tax net operating losses and lower R&D spending.
  • Cash flow: Cash used in operating activities was $4.82 million, compared with $4.65 million. There were no investing or financing cash flows reported for either quarter. Cash declined from $41.71 million at September 30 to $36.89 million at December 31.
  • Balance sheet: Working capital was approximately $37.8 million; total assets were $111.7 million and total liabilities were $10.7 million. Reported liabilities include payables, accruals, lease liabilities and deferred taxes; the filing does not report borrowings on the balance sheet.

Material changes and business developments

  • The $3.59 million New Jersey NOL-sale gain was a significant, non-operating item and was not present in the prior-year quarter.
  • The FDA BLA for I/ONTAK was filed in September 2022. The filing describes I/ONTAK as a late-stage immunotherapy candidate for cutaneous T-cell lymphoma.
  • Mino-Lok remained in a Phase 3 trial; the company added a clinical research organization to support expansion to sites outside the United States. Halo-Lido remained in a Phase 2b trial.
  • On February 7, 2023, after quarter-end, stockholders approved a 2023 stock incentive plan covering up to 12.035 million shares, including shares carried over from the 2021 plan.

Outlook, risks and contingencies

  • Management estimated that cash resources at December 31, 2022 would fund operations through February 2024. Continued operations beyond then depend on product approvals and commercialization, or additional capital, partnerships or out-licensing; management gave no assurance these will be achieved on acceptable terms.
  • The company expected R&D spending to stabilize in fiscal 2023 while focusing on I/ONTAK commercialization and completing the Mino-Lok and Halo-Lido trials.
  • Key risks include clinical and regulatory outcomes, commercialization and market acceptance, access to financing, and reliance on personnel, suppliers and strategic partners. The company stated there had been no change in risk factors since its September 30, 2022 Form 10-K.
  • License agreements create potential future milestone, royalty and other payment obligations, including under the I/ONTAK, NoveCite and Mino-Wrap arrangements. These amounts are contingent on specified development, regulatory, sales or licensing events.
  • The filing reported no legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of December 31, 2022.

Important facts for investors to verify

  1. Subsequent regulatory developments for I/ONTAK, including FDA review status, approval timing and any conditions affecting commercialization.
  2. Actual cash burn and whether the stated runway through February 2024 remains achievable, particularly if development or launch costs change.
  3. Progress, timelines and costs for the Mino-Lok Phase 3 and Halo-Lido Phase 2b trials.
  4. The impact of the one-time NOL-sale gain on comparisons with recurring operating performance.
  5. Potential dilution: at December 31, 2022, 38.24 million warrants and 13.25 million Citius stock options were outstanding; also verify the effect of the subsequently approved stock plan.